Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

BACKGROUND: Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have remarkable clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the breakdown of immune escape causes a variety of immune-related adverse events (irAEs). With t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiaoying, Roudi, Raheleh, Dai, Ting, Chen, Shangya, Fan, Bin, Li, Hongjin, Zhou, Yaqiong, Zhou, Min, Zhu, Bo, Yin, Chengqian, Li, Bin, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558759/
https://www.ncbi.nlm.nih.gov/pubmed/31182061
http://dx.doi.org/10.1186/s12885-019-5701-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558759/
https://www.ncbi.nlm.nih.gov/pubmed/31182061
http://dx.doi.org/10.1186/s12885-019-5701-6

Ejemplares similares